[EN] SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT [FR] COMPOSÉS DE CYCLOPROPYLE SUBSTITUÉS, COMPOSITIONS CONTENANT CES COMPOSÉS ET MÉTHODES DE TRAITEMENT
[EN] SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT [FR] COMPOSÉS DE CYCLOPROPYLE SUBSTITUÉS, COMPOSITIONS CONTENANT CES COMPOSÉS ET MÉTHODES DE TRAITEMENT
SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AS WELL AS THEIR USE IN TREATING TYPE-2 DIABETES
申请人:Merck Sharp & Dohme Corp.
公开号:EP2760855B1
公开(公告)日:2017-03-15
US20140256699A1
申请人:——
公开号:US20140256699A1
公开(公告)日:2014-09-11
US9422266B2
申请人:——
公开号:US9422266B2
公开(公告)日:2016-08-23
[EN] SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT<br/>[FR] COMPOSÉS DE CYCLOPROPYLE SUBSTITUÉS, COMPOSITIONS CONTENANT CES COMPOSÉS ET MÉTHODES DE TRAITEMENT
申请人:MERCK SHARP & DOHME
公开号:WO2013048916A1
公开(公告)日:2013-04-04
Substituted cyclopropyl compounds of the formula I and the pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the g-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included. Another aspect of the invention that is of interest relates to compounds of formula la.